Congenital Adrenal Hyperplasia Treatment in Transition: Innovations, Setbacks, and Strategic Shifts Shaping the Market
Congenital Adrenal Hyperplasia Treatment Milestones Congenital adrenal hyperplasia (CAH) is a rare genetic disorder affecting adrenal gland hormone production, primarily cortisol and aldosterone. Over the decades, glucocorticoids and mineralocorticoids have remained the cornerstone of congenital adrenal hyperplasia treatment , but these therapies often carry long-term risks such as growth suppression and metabolic disturbances. Recent developments, however, signal a pivotal moment in CAH care. Novel steroid-sparing options and hormone-regulating agents are now being tested in congenital adrenal hyperplasia clinical trials , aiming to address the underlying disease mechanism while minimizing side effects. One significant milestone includes the development of CRF1 receptor antagonists and gene therapy approaches designed to restore normal adrenal function. Advancements in extended-release and modified steroid formulations are also under evaluation, helping to maintain better hormo...